Results for "chronic illness"
Asthma
Asthma is a common long-term inflammatory disease of the airways. It is characterized by variable and recurring symptoms and reduced lung function. Symptoms include episodes of wheezing, coughing, chest tightness, and shortness of breath. A sudden wo
Health & MedicineDiabetes Mellitus
** Diabetes mellitus is a chronic endocrine disorder marked by persistently elevated blood glucose due to insufficient insulin production, insulin resistance, or both, leading to systemic complications if not properly managed. **CONTENT:** ## Overview Diabetes mellitus, often simply called **diabetes**, comprises a group of metabolic diseases in which the body cannot maintain normal glucose homeostasis. Glucose is the primary fuel for cells, and its regulation depends on the hormone **insulin**, secreted by the pancreatic β‑cells. In **type 1 diabetes**, an autoimmune attack destroys these β‑cells, resulting in little or no insulin. In **type 2 diabetes**, the majority of cases worldwide, the pancreas initially produces insulin but peripheral tissues become **insulin‑resistant**, forcing the organ to work harder until it eventually fails. A third, less common form—**gestational diabetes**—arises during pregnancy and usually resolves after delivery, though it raises future risk for both mother and child. Classic clinical features are the “three Ps”: **polydipsia** (excessive thirst), **polyuria** (frequent urination), and **polyphagia** (increased hunger), often accompanied by unintentional **weight loss**, blurred vision, and fatigue. Diagnosis relies on laboratory criteria such as fasting plasma glucose ≥126 mg/dL, a 2‑hour oral glucose tolerance test ≥200 mg/dL, or an HbA1c ≥6.5 %. If left untreated, chronic hyperglycemia damages blood vessels and nerves, precipitating a spectrum of **microvascular** (retinopathy, nephropathy, neuropathy) and **macrovascular** (coronary artery disease, stroke, peripheral arterial disease) complications. These sequelae account for the disease’s high mortality: roughly **4.2 million deaths** per year worldwide, with about **1.5 million** directly attributable to untreated or poorly controlled diabetes. Early detection, lifestyle modification, and individualized pharmacotherapy are essential to prevent or delay these outcomes. **Anyone experiencing persistent symptoms or at high risk (e.g., family history, obesity, sedentary lifestyle) should seek professional medical evaluation promptly.** ## History/Background The earliest written record of diabetes dates to an Egyptian papyrus (c. 1500 BC) describing “excessive urination.” The term “diabetes” (Greek for “siphon”) was coined by the physician **Aretaeus of Cappadocia** in the 2nd century AD, while **Madhava** of India noted the sweet taste of urine in the 6th century. In 1869, **Paul Langerhans** identified the pancreatic islets (now called **Langerhans islets**) that later proved to be the source of insulin. The breakthrough came in 1921–1922 when **Frederick Banting**, **Charles Best**, and **John Macleod** isolated insulin, enabling life‑saving therapy for type 1 diabetes. The mid‑20th century saw the rise of **type 2 diabetes** as a public health issue, linked to urbanization, dietary changes, and obesity. The **World Health Organization** (WHO) officially recognized diabetes as a global epidemic in the 1990s, prompting the first **International Diabetes Federation (IDF)** conference in 1999. Since then, diagnostic criteria have been refined (e.g., introduction of HbA1c as a diagnostic test in 2010) and novel drug classes—**metformin**, **GLP‑1 receptor agonists**, **SGLT2 inhibitors**—have expanded therapeutic options. ## Key Information - **Classification:** Type 1, Type 2, Gestational, and specific monogenic forms (MODY, neonatal diabetes). - **Epidemiology:** Over 537 million adults (≈ 10 % of the global population) live with diabetes; prevalence is rising fastest in low‑ and middle‑income countries. - **Pathophysiology:** - *Insulin deficiency*: autoimmune β‑cell destruction (type 1) or β‑cell exhaustion (type 2). - *Insulin resistance*: impaired signaling in muscle, adipose, and hepatic tissue, often driven by excess adiposity and inflammatory cytokines. - **Diagnostic thresholds:** Fasting glucose ≥126 mg/dL, 2‑hour OGTT ≥200 mg/dL, HbA1c ≥6.5 %, or random glucose ≥200 mg/dL with classic symptoms. - **Management pillars:** 1. **Lifestyle:** balanced diet (Mediterranean or DASH patterns), regular aerobic and resistance exercise, weight control. 2. **Pharmacotherapy:** metformin first‑line for type 2; insulin for type 1 and advanced type 2; adjunct agents (SGLT2 inhibitors, GLP‑1 agonists) for cardiovascular/renal protection. 3. **Monitoring:** self‑monitoring of blood glucose (SMBG), periodic HbA1c, blood pressure, lipid profile, and screening for complications (annual retinal exam, urine albumin, foot exam). - **Complications:** - *Microvascular*: diabetic retinopathy (leading cause of blindness), diabetic nephropathy (major cause of end‑stage renal disease), peripheral neuropathy (risk of foot ulcers). - *Macrovascular*: accelerated atherosclerosis, increased risk of myocardial infarction and stroke. - **Prevention:** Primary prevention focuses on obesity reduction, physical activity, and dietary quality; secondary prevention emphasizes early detection and tight glycemic control. ## Significance Diabetes mellitus is a **public health priority** because it intersects with virtually every organ system and amplifies the burden of cardiovascular disease, the leading cause of death worldwide. Economically, the disease imposes staggering costs—estimated at **US $966 billion** in 2021—through direct medical expenses and lost productivity. The advent of newer drug classes that confer **cardiorenal protection** has reshaped treatment algorithms, underscoring the importance of a **multidisciplinary approach** involving endocrinologists, primary care physicians, dietitians, diabetes educators, and mental‑health professionals. Beyond the clinical realm, diabetes drives research innovation: **continuous glucose monitoring (CGM)**, **automated insulin delivery (“artificial pancreas”)**, and **gene‑editing therapies** for monogenic forms are rapidly moving from bench to bedside. Public‑health initiatives such as the WHO’s **Global Diabetes Compact** aim to halve premature deaths from diabetes by 2030, emphasizing early screening, equitable access to medicines, and health‑promoting policies. **For anyone suspecting diabetes or managing the condition, regular follow‑up with a qualified health professional is essential** to tailor therapy, monitor for complications, and adjust lifestyle measures. Early, evidence‑based intervention can dramatically improve quality of life and longevity. **INFOBOX:** - Name: Diabetes mellitus - Type: Chronic endocrine/metabolic disorder - Date: First clinical description c. 1500 BC; modern insulin therapy 1922 - Location: Worldwide (global prevalence) - Known For: Persistent hyperglycemia, insulin deficiency or resistance, and systemic complications **TAGS:** diabetes, insulin, hyperglycemia, type 1 diabetes, type 2 diabetes, metabolic disease, chronic illness, public health
Health & MedicinePsoriasis
** Psoriasis is a chronic, non‑contagious autoimmune skin disorder that produces red, scaly plaques ranging from isolated patches to full‑body involvement. **CONTENT:** ## Overview Psoriasis is a long‑lasting autoimmune disease in which the immune system mistakenly accelerates the growth cycle of skin cells. Normally, epidermal cells mature over about a month; in psoriasis, this process is compressed to just three to four days, causing a buildup of immature cells that appear as **thick, silvery‑white scales** on a background of inflamed, reddish skin. The lesions can be **painful, itchy, and sometimes bleed** when scratched, and they may appear on the scalp, elbows, knees, lower back, and nails. While the condition is **non‑contagious**, its visibility can lead to significant psychosocial distress, affecting self‑esteem, work productivity, and quality of life. The disease exhibits a wide spectrum of severity. Some individuals experience **mild, localized plaques** that respond to over‑the‑counter moisturizers, whereas others develop **moderate to severe disease** that covers large body areas and may be associated with systemic inflammation. Psoriasis is also linked with comorbidities such as **psoriatic arthritis**, cardiovascular disease, metabolic syndrome, and depression. Because of these associations, psoriasis is increasingly viewed as a **systemic inflammatory disorder**, not merely a skin problem. A hallmark trigger is the **Koebner phenomenon**, where skin injury—such as a cut, scrape, or even a tattoo—induces new psoriatic plaques at the site of trauma. Other common triggers include infections (especially streptococcal throat infections), stress, smoking, alcohol, certain medications (e.g., beta‑blockers, lithium), and climate changes. Recognizing these factors helps patients and clinicians tailor lifestyle modifications alongside medical therapy. ## History/Background Descriptions of scaly skin eruptions date back to ancient Egypt (the Ebers Papyrus, c. 1550 BC) and classical Greek writings, where physicians noted “the disease of the king’s skin.” The term **psoriasis** derives from the Greek *psōr* (“itch”) and *‑iasis* (“condition”). In the 19th century, **Robert Willan** and **Robert Wood** classified skin diseases, distinguishing psoriasis from eczema. The autoimmune nature was not recognized until the mid‑20th century, when **M. M. Kelley** and colleagues demonstrated T‑cell involvement. The discovery of **TNF‑α** and interleukin‑17 pathways in the 1990s revolutionized treatment, leading to the first biologic agents (e.g., etanercept, 2003). The **Koebner phenomenon** was first described by **Heinrich Koebner** in 1876, emphasizing the role of skin injury in disease propagation. ## Key Information - **Epidemiology:** Affects ~2–3 % of the global population, with similar prevalence across genders and ethnicities. - **Pathophysiology:** Dysregulated **Th1/Th17** immune responses cause overproduction of cytokines (IL‑17, IL‑23, TNF‑α) that stimulate keratinocyte proliferation. - **Clinical Types:** Includes plaque psoriasis (most common), guttate, inverse, pustular, and erythrodermic forms. - **Diagnosis:** Primarily clinical; skin biopsy reserved for atypical presentations. The **Psoriasis Area and Severity Index (PASI)** quantifies disease burden. - **Treatment Spectrum:** - *Topical*: corticosteroids, vitamin D analogues, retinoids, coal tar. - *Phototherapy*: narrow‑band UVB, excimer laser. - *Systemic non‑biologic*: methotrexate, cyclosporine, acitretin. - *Biologic agents*: TNF inhibitors, IL‑12/23 inhibitors, IL‑17 inhibitors, IL‑23 inhibitors. - **Lifestyle Management:** Moisturizing, smoking cessation, weight control, stress reduction, and avoidance of known triggers. - **When to Seek Professional Care:** Immediate evaluation is warranted for sudden widespread redness (erythroderma), severe joint pain suggesting psoriatic arthritis, or if topical measures fail to control symptoms. Persistent lesions that bleed, develop infection, or cause significant emotional distress should also prompt a dermatologist visit. ## Significance Psoriasis is more than a cosmetic concern; it serves as a **model disease** for understanding autoimmunity and the skin‑immune axis. The development of targeted biologics has not only transformed psoriasis care but also paved the way for therapies in other inflammatory conditions, such as inflammatory bowel disease and rheumatoid arthritis. Economically, psoriasis imposes a substantial burden through direct medical costs and indirect losses from work absenteeism. Psychologically, the visible nature of lesions can lead to stigma, anxiety, and depression, underscoring the need for holistic management that includes mental‑health support. Ongoing research into the genetic basis (e.g., **HLA‑C*06:02**) and microbiome interactions promises to refine personalized treatment strategies, moving the field toward **precision dermatology**. **INFOBOX:** - Name: Psoriasis - Type: Chronic autoimmune skin disease - Date: First documented in ancient medical texts; modern classification established 19th century - Location: Worldwide; prevalence ~2–3 % of population - Known For: Red, scaly plaques; Koebner phenomenon; pioneering role in biologic therapy development **TAGS:** dermatology, autoimmune disease, skin disorders, chronic illness, biologic therapy, Koebner phenomenon, psoriatic arthritis, public health
Health & MedicineCrohns Disease
** Crohn’s disease is a chronic inflammatory bowel disease that can affect any part of the gastrointestinal tract, causing abdominal pain, diarrhea, weight loss, and a range of extra‑intestinal complications. **CONTENT:** ## Overview Crohn’s disease belongs to the family of inflammatory bowel diseases (IBD), a group of disorders characterized by persistent inflammation of the gastrointestinal (GI) tract. Unlike ulcerative colitis, which is limited to the colon and rectum, **Crohn’s disease** may involve any segment from the mouth to the anus, most commonly the terminal ileum and colon. The inflammation is transmural, meaning it penetrates the full thickness of the bowel wall, which predisposes patients to strictures, fistulas, and perforation. Typical symptoms include **abdominal pain**, **persistent diarrhea**, **fever**, **abdominal distension**, and **unintended weight loss**. Because the disease is systemic, many patients also experience **fatigue**, **anemia**, **arthritis**, **eye inflammation (uveitis or episcleritis)**, and characteristic **skin lesions** such as **erythema nodosum** and **pyoderma gangrenosum**. The course of Crohn’s disease is highly variable; some individuals have mild, intermittent flares, while others endure severe, progressive disease that necessitates surgery. Diagnosis relies on a combination of clinical assessment, laboratory tests (e.g., C‑reactive protein, fecal calprotectin), endoscopic evaluation with biopsies, and cross‑sectional imaging (CT or MR enterography). Treatment is multidisciplinary, aiming to induce remission, maintain symptom‑free intervals, and prevent complications. Therapeutic options include **aminosalicylates**, **corticosteroids**, **immunomodulators** (azathioprine, methotrexate), **biologic agents** targeting tumor necrosis factor‑α (TNF‑α) or integrins, and, when necessary, surgical resection of diseased segments. Patients with Crohn’s disease should seek professional medical care promptly if they develop new or worsening abdominal pain, persistent high‑grade fever, signs of intestinal obstruction (vomiting, inability to pass gas or stool), or extra‑intestinal manifestations such as severe joint swelling or eye redness. Early intervention can reduce the risk of irreversible bowel damage and improve quality of life. ## History/Background The condition now known as Crohn’s disease was first described in a landmark 1932 paper by **Burrill B. Crohn**, **Leon G. Ginzburg**, and **Egon S. Oppenheimer** at Mount Sinai Hospital in New York. Their report detailed 14 patients with “regional ileitis,” distinguishing it from ulcerative colitis and other gastrointestinal disorders. The eponym “Crohn’s disease” gradually supplanted the original term, although the contributions of Ginzburg and Oppenheimer are increasingly recognized in modern histories. Throughout the mid‑20th century, the disease was considered rare, but epidemiologic studies in the 1970s and 1980s revealed a rising incidence in industrialized nations, suggesting environmental and lifestyle influences. The discovery of **genetic susceptibility loci**—most notably the **NOD2/CARD15** gene in the early 2000s—provided a molecular foothold for research. Subsequent genome‑wide association studies identified over 200 risk alleles, highlighting the complex interplay of genetics, the gut microbiome, and immune dysregulation. Therapeutic milestones include the introduction of **corticosteroids** in the 1950s, the approval of **azathioprine** for maintenance therapy in the 1970s, and the revolutionary launch of **infliximab**, the first anti‑TNF biologic, in 1998. These advances transformed Crohn’s disease from a condition often requiring extensive surgery to one that can be medically managed for many patients. ## Key Information - **Epidemiology:** Affects 3–20 per 100,000 individuals worldwide; peak onset between ages 15–35; slight female predominance in some regions. - **Pathophysiology:** Multifactorial—genetic predisposition (e.g., NOD2, IL23R), abnormal immune response to intestinal microbiota, and environmental triggers (smoking, diet, antibiotics). - **Clinical Features:** Abdominal pain (often RLQ), non‑bloody diarrhea, weight loss, low‑grade fever, perianal disease (fistulas, abscesses). Extra‑intestinal: anemia, erythema nodosum, pyoderma gangrenosum, arthritis, uveitis, primary sclerosing cholangitis. - **Complications:** Bowel obstruction from strictures, fistula formation, malabsorption, nutritional deficiencies, increased risk of **colorectal cancer** (especially after 8–10 years of disease) and **small‑bowel adenocarcinoma**. - **Diagnostic Tools:** Colonoscopy with ileal intubation, capsule endoscopy, MR/CT enterography, serologic markers (ASCA, pANCA), fecal calprotectin. - **Management:** Induction of remission (corticosteroids, budesonide, biologics), maintenance (immunomodulators, anti‑TNF agents, anti‑integrins, ustekinumab), nutritional therapy (enteral formulas, exclusive liquid diets), and surgery (strictureplasty, resection) when medically refractory. - **Monitoring:** Regular colonoscopic surveillance beginning 8–10 years after diagnosis, especially for colonic involvement, to detect dysplasia early. ## Significance Crohn’s disease exemplifies the challenges of chronic immune‑mediated disorders: it imposes a lifelong burden on patients, families, and health‑care systems. The disease’s unpredictable flares and potential for serious complications demand coordinated care involving gastroenterologists, surgeons, nutritionists, rheumatologists, dermatologists, and mental‑health professionals. Advances in biologic therapy have dramatically improved remission rates and reduced the need for surgery, yet many patients still experience refractory disease, underscoring the need for novel targets and personalized medicine. Beyond individual health, Crohn’s disease has spurred broader scientific insights into gut immunity, the microbiome, and the genetics of complex diseases. Research on Crohn’s has catalyzed the development of anti‑TNF agents now used across rheumatology, dermatology, and oncology. Public awareness and advocacy have also grown, leading to better insurance coverage for biologics and support for patient‑focused research. As the global incidence continues to rise, especially in newly industrialized nations, understanding and managing Crohn’s disease remains a public‑health priority. **INFOBOX:** - Name: Crohn’s disease (regional ileitis) - Type: Chronic inflammatory bowel disease (IBD) - Date: First described 1932 - Location: Can affect any part of the gastrointestinal tract (mouth to anus) - Known For: Transmural inflammation, extra‑intestinal manifestations, and increased cancer risk **TAGS:** inflammatory bowel disease, gastroenterology, autoimmune disease, chronic illness, biologic therapy, intestinal cancer, extra‑intestinal manifestations, patient education
Health & MedicineConditions Encyclopedia Entry 1777139884
Cystic fibrosis (CF) is a chronic, progressive genetic disorder that affects the respiratory, digestive, and reproductive systems, causing severe damage and impairing the body's ability to function properly.
Health & MedicineHepatitis
** Hepatitis is inflammation of the liver that can be caused by viruses, toxins, autoimmune reactions, or metabolic disorders, presenting with a spectrum from silent infection to severe liver failure. **CONTENT:** ## Overview **Hepatitis** refers to inflammation of liver tissue, a vital organ responsible for metabolism, detoxification, protein synthesis, and bile production. The condition can arise from a wide array of triggers, including infectious agents (most famously hepatitis A‑E viruses), excessive alcohol consumption, certain medications, metabolic diseases such as non‑alcoholic fatty liver disease, and autoimmune processes. While many individuals experience no noticeable symptoms, others develop classic signs such as **jaundice** (yellowing of the skin and sclerae), loss of appetite, nausea, vomiting, fatigue, right‑upper‑quadrant abdominal pain, and diarrhea. Laboratory testing typically reveals elevated liver enzymes (ALT, AST) and, depending on the cause, specific serologic markers. Hepatitis is classified by duration: **acute hepatitis** resolves within six months, whereas **chronic hepatitis** persists beyond that point. Acute disease may clear spontaneously, evolve into a chronic state, or—rarely—progress to **acute liver failure**, a medical emergency marked by rapid loss of hepatic function, coagulopathy, and encephalopathy. Chronic hepatitis carries a long‑term risk of **fibrosis**, **cirrhosis**, **hepatic decompensation**, and **hepatocellular carcinoma** (liver cancer). Early detection, appropriate treatment, and lifestyle modifications are essential to prevent these complications. Anyone experiencing persistent jaundice, severe abdominal pain, confusion, or unexplained weight loss should seek professional medical evaluation promptly. ## History/Background The term “hepatitis” entered medical literature in the early 19th century, derived from the Greek *hepar* (liver) and *-itis* (inflammation). Early descriptions were vague, often conflating liver inflammation with other abdominal ailments. The first viral cause was identified in 1945 when Dr. Baruch Blumberg discovered the hepatitis B surface antigen, later earning a Nobel Prize. The 1970s saw the isolation of hepatitis A virus (HAV) and the recognition of non‑A, non‑B hepatitis, which was later identified as hepatitis C (HCV) in 1989. Hepatitis D (HDV) and E (HEV) were characterized in the 1980s and 1990s, respectively. Vaccines for HAV and HBV were introduced in the 1990s, dramatically reducing incidence in many countries. In the 21st century, direct‑acting antiviral (DAA) regimens transformed HCV therapy, achieving cure rates above 95 % and reshaping public‑health strategies worldwide. ## Key Information - **Etiology:** Viral (HAV, HBV, HCV, HDV, HEV), alcoholic, drug‑induced (e.g., acetaminophen overdose, isoniazid), autoimmune, metabolic (e.g., Wilson disease, non‑alcoholic steatohepatitis). - **Transmission:** Fecal‑oral (HAV, HEV), blood‑borne or sexual (HBV, HCV, HDV), vertical (mother‑to‑child), and iatrogenic (contaminated medical equipment). - **Diagnosis:** Liver function tests, serologic panels (HBsAg, anti‑HBc, anti‑HCV, anti‑HAV IgM/IgG), PCR for viral RNA/DNA, imaging (ultrasound, elastography), and liver biopsy when indicated. - **Management:** Supportive care for most acute cases; antiviral therapy for HBV (nucleos(t)ide analogues) and HCV (DAAs); immunosuppression for autoimmune hepatitis; cessation of alcohol and hepatotoxic drugs; nutritional support and vaccination (HAV, HBV). - **Prevention:** Safe injection practices, blood screening, vaccination, hand hygiene, and public education. - **Prognosis:** Acute viral hepatitis often resolves without sequelae; chronic HBV/HCV can lead to cirrhosis in 20‑30 % of patients over decades; effective antiviral therapy markedly reduces progression risk. ## Significance Hepatitis remains a global health priority, accounting for an estimated 1.5 million deaths annually from cirrhosis and liver cancer. The burden is unevenly distributed, with low‑ and middle‑income regions experiencing higher rates of viral hepatitis due to limited vaccination, screening, and treatment infrastructure. The development of HBV vaccines and curative HCV regimens illustrates how scientific advances can translate into massive public‑health gains, underscoring the importance of continued research, equitable access to care, and robust surveillance. Moreover, hepatitis serves as a model for interdisciplinary collaboration among virology, immunology, pharmacology, and health policy, shaping approaches to other chronic infectious diseases. **When to Seek Care:** If you notice yellowing of the eyes or skin, persistent fatigue, abdominal swelling, dark urine, pale stools, or sudden confusion, contact a healthcare professional immediately. Early evaluation can differentiate benign, self‑limited hepatitis from conditions requiring urgent intervention, such as acute liver failure or rapidly progressive chronic disease. **INFOBOX:** - Name: Hepatitis (Inflammation of the Liver) - Type: Medical condition / Infectious disease - Date: First described in the 1800s; modern viral classifications established 1945‑1990 - Location: Worldwide (prevalence varies by region and etiology) - Known For: Leading cause of chronic liver disease, cirrhosis, and liver cancer; successful vaccine and antiviral breakthroughs **TAGS:** liver disease, viral hepatitis, chronic illness, public health, vaccination, antiviral therapy, cirrhosis, hepatocellular carcinoma
Health & MedicineConditions Encyclopedia Entry 1778068925
Cystic fibrosis (CF) is a genetic disorder that affects the respiratory, digestive, and reproductive systems, causing severe damage and premature death if left untreated.
Health & MedicineConditions Encyclopedia Entry 1778002264
Cystic fibrosis is a chronic, genetic disorder that affects the respiratory, digestive, and reproductive systems, causing severe damage and early mortality if left untreated.
Health & MedicineConditions Encyclopedia Entry 1780642808
Alopecia areata is a chronic autoimmune skin condition characterized by patchy hair loss on the scalp, face, or body.
Health & MedicineConditions Encyclopedia Entry 1778313306
Cystic fibrosis (CF) is a chronic, genetic disorder that affects the respiratory, digestive, and reproductive systems, causing severe damage and early death if left untreated.
Health & MedicineConditions Encyclopedia Entry 1777964044
Cystic fibrosis (CF) is a chronic and progressive genetic disorder that affects the respiratory, digestive, and reproductive systems, causing severe damage and potentially life-threatening complications.
Health & MedicineConditions Encyclopedia Entry 1778836024
Cystic fibrosis (CF) is a chronic, progressive genetic disorder that affects the respiratory, digestive, and reproductive systems, causing severe damage and complications if left untreated.
Health & MedicineConditions Encyclopedia Entry 1781460986
** This entry is about a rare and debilitating neurological disorder known as **Stiff Person Syndrome (SPS)**, characterized by progressive muscle stiffness and rigidity. **CONTENT:** ### Overview Stiff Person Syndrome (SPS) is a rare and chronic neurological disorder that affects approximately 1 in 1 million people worldwide. The condition is characterized by progressive muscle stiffness and rigidity, which can lead to significant mobility impairment and disability. SPS is often misdiagnosed or underdiagnosed due to its rarity and the lack of awareness among healthcare professionals. However, with proper diagnosis and treatment, patients with SPS can experience significant improvements in their quality of life. The symptoms of SPS can vary in severity and progression, but they typically begin with stiffness in the lower back and legs, which can spread to other parts of the body over time. Patients may experience muscle spasms, tremors, and difficulty walking or performing daily activities. In some cases, SPS can be associated with other autoimmune disorders, such as **Multiple Sclerosis (MS)** or **Lupus**. ### History/Background The first reported cases of SPS date back to the 1950s, but it wasn't until the 1960s that the condition was formally described in the medical literature. Since then, research has been ongoing to understand the underlying causes and mechanisms of SPS. In 2010, a study published in the journal **Neurology** identified a specific **autoantibody** associated with SPS, which has since become a key diagnostic marker for the condition. ### Key Information **Key Facts:** * SPS is a rare neurological disorder that affects approximately 1 in 1 million people worldwide. * The condition is characterized by progressive muscle stiffness and rigidity. * SPS can be associated with other autoimmune disorders, such as MS or Lupus. * The symptoms of SPS can vary in severity and progression. * Proper diagnosis and treatment can significantly improve quality of life. **Key Statistics:** * SPS affects more women than men, with a female-to-male ratio of 3:1. * The average age of onset is 40-50 years old. * SPS can occur at any age, but it is most commonly diagnosed in middle-aged adults. ### Significance SPS is a debilitating condition that can significantly impact a person's quality of life. However, with proper diagnosis and treatment, patients can experience significant improvements in their mobility and daily functioning. Research into SPS has also shed light on the underlying mechanisms of autoimmune disorders and has led to the development of new diagnostic markers and treatment strategies. **INFOBOX:** - Name: Stiff Person Syndrome (SPS) - Type: Neurological disorder - Date: 1950s (first reported cases) - Location: Worldwide - Known For: Progressive muscle stiffness and rigidity **TAGS:** Neurological disorder, autoimmune disorder, muscle stiffness, rigidity, progressive disease, rare condition, chronic illness, mobility impairment, disability, quality of life, diagnosis, treatment, research, autoimmune mechanisms, diagnostic markers, treatment strategies.
Health & MedicineConditions Encyclopedia Entry 1779107539
Cystic Fibrosis (CF) is a genetic disorder that affects the respiratory, digestive, and reproductive systems, causing thick, sticky mucus to build up in the lungs, pancreas, and other organs.